Why Is Exelixis (EXEL) Up 3.8% Since Last Earnings Report?

Exelixis (EXEL) reported mixed Q2 2025 results, with adjusted EPS of $0.75 exceeding consensus estimates, but net revenues of $568.3 million missing due to a 70% year-over-year drop in collaboration revenue, despite strong 18.8% growth in product sales led by Cabometyx. The company maintained its 2025 guidance and announced positive Phase III STELLAR-303 results for zanzalintinib in metastatic colorectal cancer, demonstrating improved overall survival. Additionally, Exelixis secured a Cabometyx FDA label expansion for neuroendocrine tumors and settled patent litigation for generic entry in 2031, highlighting a strategic pipeline focus and continued commercial strength for its key oncology assets.

Analysis

Exelixis presented a mixed but fundamentally strong Q2 2025 financial report. While total net revenues of $568.3 million missed consensus estimates and fell 10.8% year-over-year, this decline was entirely attributable to a 70% drop in collaboration revenues due to a difficult comparison against a $150 million milestone payment in the prior-year quarter. The core business demonstrated significant strength, with net product revenues growing a robust 18.8% year-over-year to $520 million, driven by increased sales volume of its flagship drug, Cabometyx. The recent FDA label expansion for Cabometyx in neuroendocrine tumors (NET) is already contributing over 4% to demand, signaling a new avenue for organic growth. Beyond current commercial performance, the company's pipeline has been significantly de-risked by positive top-line results from the phase III STELLAR-303 study, where its next-generation TKI, zanzalintinib, showed a statistically significant improvement in overall survival. This pipeline progress is complemented by a solid financial strategy, evidenced by the maintenance of full-year 2025 guidance, an aggressive stock repurchase program with $204 million remaining, and a patent settlement that secures Cabometyx's U.S. market exclusivity until January 2031, ensuring a long-term revenue stream.

Key Decisions for Investors

• Investors should look past the headline revenue miss, which was distorted by a non-recurring prior-year milestone, and instead focus on the 18.8% year-over-year growth in underlying product sales as a more accurate indicator of operational health.
• The positive overall survival data for zanzalintinib in the STELLAR-303 trial is a major catalyst; monitor for further updates on this asset as it represents the company's next significant growth driver beyond Cabometyx.
• Consider the company's strong value proposition, supported by a long patent runway for Cabometyx until 2031, maintained full-year guidance, and an aggressive share buyback program that signals management's confidence.
• Note the disciplined but active portfolio management, including the discontinuation of the STELLAR-305 trial, which reflects a rational allocation of capital towards higher-potential assets but also underscores inherent clinical development risks.